NOV 17, 202656 MINS READ
Creatine phosphate (phosphocreatine, N-(alpha-imino-alpha-phosphonamido)-methyl-N-methylglycine) serves as the primary high-energy phosphate reserve in vertebrate tissues, particularly within skeletal and cardiac muscle 2. The molecule features a phosphamide bond (N-P) rather than the pyrophosphate bond (O-P) characteristic of ATP, conferring significantly higher free energy of hydrolysis (ΔG°' ≈ -43 kJ/mol vs. -30.5 kJ/mol for ATP) 17,18. This thermodynamic advantage enables creatine phosphate to function as an immediate ATP buffer during periods of intense energy demand, with intracellular concentrations reaching 20-35 mM in skeletal muscle and 10-15 mM in cardiac tissue 17,18.
The creatine kinase (CK) system catalyzes the reversible transfer of the phosphoryl group from creatine phosphate to ADP, regenerating ATP within milliseconds—substantially faster than glycolytic or oxidative phosphorylation pathways 4,5. This reaction is particularly critical during the initial seconds of maximal muscle contraction and in maintaining contractility in ischemic myocardium where oxidative metabolism is compromised 2,3. Beyond energy buffering, the CK system facilitates intracellular energy transport, with mitochondrial CK isoforms generating creatine phosphate that diffuses to cytosolic sites of ATP consumption, effectively creating a "phosphocreatine shuttle" 1,4.
Pharmaceutical-grade creatine phosphate is typically supplied as the disodium salt tetrahydrate (C₄H₈N₃Na₂O₅P·4H₂O, molecular weight ~327 g/mol anhydrous, ~399 g/mol hydrated), which exhibits enhanced aqueous solubility (>300 mM at physiological pH) compared to the free acid form 15. The compound exists predominantly in zwitterionic form at physiological pH (7.4), with calculated pKa values of approximately 2.7 (phosphate), 4.5 (guanidinium), and 14.3 (terminal amine) 9,13.
Pharmaceutical-grade creatine phosphate must satisfy rigorous purity and safety criteria established by pharmacopeial standards (USP, EP, JP). Key specifications include:
Stability testing under ICH conditions (25°C/60% RH, 40°C/75% RH) demonstrates that pharmaceutical-grade creatine phosphate disodium salt maintains >95% potency for 24 months when stored in moisture-barrier packaging with desiccant 2,15. The compound exhibits pH-dependent stability, with optimal storage at pH 8.0-12.0 where hydrolysis rates are minimized (t₁/₂ >6 months at pH 10, 25°C) 15. In contrast, at physiological pH 7.4, aqueous solutions show significant degradation (t₁/₂ ~48 hours at 37°C), necessitating lyophilized powder formulations or high-pH concentrates (pH 9-11) that are diluted immediately before administration 9,12,15.
The predominant industrial synthesis route involves direct phosphorylation of creatine using phosphorus oxychloride (POCl₃) under controlled conditions 2. The optimized process comprises:
Typical yields range from 65-75% based on creatine input, with process optimization focusing on minimizing dihydrotriazine formation (favored at pH <6) and creatinine generation (via cyclization at elevated temperatures) 2,14.
An alternative enzymatic route employs recombinant creatine kinase (CK) to catalyze phosphoryl transfer from ATP to creatine under mild conditions (pH 7.5-8.5, 25-37°C) 7,8. This approach offers advantages in stereoselectivity and reduced impurity profiles but faces challenges in ATP cost and enzyme stability, limiting commercial scalability. Immobilized CK on agarose or magnetic nanoparticles has been explored to enable enzyme recycling, achieving >20 reaction cycles with <15% activity loss 7.
Recent patent literature describes synthesis of membrane-permeable creatine phosphate prodrugs designed to overcome the poor cellular uptake of the highly polar parent compound 1,4,5,9,10,11,12,13. Representative prodrug structures include:
These prodrugs demonstrate stability in simulated gastric fluid (pH 1.2, t₁/₂ >4 hours) and rapid conversion to creatine phosphate in cytosolic S9 fractions (t₁/₂ 15-45 minutes), with intracellular creatine phosphate concentrations reaching 2-8 mM following 100 μM prodrug treatment in HEK293 and Caco-2 cell lines 9,10,12.
Parenteral creatine phosphate is primarily formulated as lyophilized powder for reconstitution or as high-concentration alkaline solutions requiring dilution before administration 2,15. Standard formulations include:
Typical clinical dosing regimens involve intravenous infusion of 1-4 g/day (divided doses of 0.5-1 g every 6-12 hours) for treatment of acute myocardial infarction, heart failure, or muscular dystrophy, with plasma half-life of 4-6 hours necessitating repeated administration 2,3.
Due to extensive first-pass metabolism and acid-catalyzed hydrolysis in the stomach (t₁/₂ ~30 minutes at pH 1.5), oral bioavailability of unprotected creatine phosphate is <5% 6. Enteric-coated formulations employing pH-sensitive polymers (Eudragit L100, hydroxypropyl methylcellulose phthalate) enable targeted release in the duodenum (pH >6.0), improving bioavailability to 15-25% 6. Formulations comprise:
Clinical studies with enteric-coated creatine phosphate (3 g/day for 8 weeks) in patients with muscular dystrophy showed modest improvements in muscle strength (10-15% increase in maximal voluntary contraction) and lean body mass (+1.2 kg vs. placebo), though effects were less pronounced than with creatine monohydrate supplementation 6.
Membrane-permeable creatine phosphate prodrugs enable oral administration without enteric coating, achieving systemic bioavailability of 40-70% 1,4,5,9,10,11. Representative formulations include:
Prodrug formulations show particular promise for CNS indications, with blood-brain barrier penetration 5-10 fold higher than creatine phosphate, achieving brain tissue concentrations of 2-5 mM following oral doses of 100-300 mg/kg in rodent models of Huntington's disease and Parkinson's disease 1,4,5,11,14.
Creatine phosphate has been extensively investigated for cardiovascular indications based on its ability to restore myocardial ATP levels and enhance contractility under ischemic conditions 2,3,16. Key applications include:
Acute Myocardial Infarction: Intravenous administration of 2-4 g/day creatine phosphate within 6 hours of symptom onset reduces infarct size (assessed by cardiac MRI) by 20-35% and lowers peak creatine phosphokinase (CPK) release by 30-45% compared to standard care alone 2,3. The mechanism involves rapid ATP regeneration in ischemic myocardium, reducing cellular energy deficit and limiting progression from reversible injury to irreversible necrosis 3,16. Clinical trials demonstrate improved left ventricular ejection fraction (LVEF) at 30 days (+5-8% absolute improvement) and reduced incidence of ventricular arrhythmias (relative risk reduction 0.65, 95% CI 0.48-0.87) 3.
Cardiac Surgery And Cardioplegia: Addition of 10-20 mM creatine phosphate to cardioplegic solutions enhances myocardial preservation during aortic cross-clamping, with post-operative benefits including 25-40% reduction in troponin I release, shorter duration of inotropic support (median reduction 8-12 hours), and improved early graft function in coronary artery bypass grafting (CABG) procedures 2,15. The magnesium salt of creatinol-O-phosphate (a synthetic analog) demonstrates superior efficacy in reducing ischemia-reperfusion injury, with 50% reduction in necrotic lesion
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| XENOPORT INC. | Oral and CNS delivery for neurodegenerative disorders (Huntington's disease, Parkinson's disease), ischemic conditions, heart failure, and genetic creatine kinase system disorders including creatine transporter deficiency. | Creatine Phosphate Prodrug Formulations | Membrane-permeable prodrugs achieve 40-70% oral bioavailability, 5-10 fold enhanced blood-brain barrier penetration, intracellular creatine phosphate concentrations of 2-8 mM, and stability in gastric fluid (pH 1.2, t1/2 >4 hours) with rapid cytosolic conversion (t1/2 15-45 minutes). |
| ALFASIGMA S.P.A. | Acute myocardial infarction treatment, cardiac surgery cardioplegia (5-20 mM in cardioplegic solutions), heart failure management, and parenteral administration requiring immediate use without reconstitution. | Stable Aqueous Phosphocreatine Injectable Solutions | Ready-to-use sterile liquid formulations at 300-700 mM concentration (pH 8.0-12.0) or ready-to-dilute concentrates (500-700 mM, pH 10-12) maintain >95% potency for 24 months, eliminating powder dissolution issues and ensuring homogeneous administration. |
| Farmington Pharma Development | Ischemic tissue protection, energy homeostasis restoration in ATP-depleted cells, treatment of genetic creatine kinase system disorders, neurodegenerative diseases, and conditions requiring sustained creatine phosphate delivery. | Creatine Phosphate Analog Prodrugs | Enhanced membrane permeability through passive diffusion or active transport, higher free energy analogs (e.g., cyclocreatine) for ATP regeneration under severe energy depletion, sustained systemic concentrations, and ability to cross blood-brain and blood-placental barriers. |
| SCHIAPPARELLI FARMACEUTICI S.P.A. | Muscular atrophy and dystrophy treatment, myocardiosclerosis, degenerative myocardiopathies, myocardial anoxia, and restoration of myocardial contractility in cardiovascular pathologies via intramuscular or intravenous administration. | Crystalline Phosphocreatine Pharmaceutical Preparations | Glycine-free crystalline phosphocreatine formulations (typically 200-400 mg dosage) meeting pharmaceutical-grade specifications (>98% purity, creatinine <100 ppm, dihydrotriazine <50 ppm) for safe high-dose administration. |
| SIMES S.P.A. | Prevention and treatment of myocardial infarction, coronary insufficiency, experimentally-induced myocardial ischemia, and cardiac surgery requiring enhanced myocardial protection beyond standard cardioplegic solutions. | Creatinol-O-Phosphate Magnesium Salt | Magnesium salt derivative demonstrates 50% reduction in ischemia-induced necrotic lesions, reduced CPK release, positive inotropic effect in anoxic heart, and superior efficacy in reducing ischemia-reperfusion injury compared to standard creatinol-O-phosphate. |